With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Until now, all available treatments, including immunotherapy—which involves strengthening the immune system to fight cancer—have proved disappointing. CAR-T cells are genetically modified immune cells manufactured in the laboratory and designed to identify and destroy cancer cells.
By targeting a protein present in the tumor environment, a team from the University of Geneva (UNIGE) and the Geneva University Hospital (HUG) has developed CAR-T cells capable of destroying glioblastoma cells. Their efficacy in an animal model of the disease paves the way for clinical trials in humans.
The results are published in the Journal for ImmunoTherapy of Cancer.
Protein homeostasis, or proteostasis, is essential for cellular proteins to function properly. The buildup of abnormal proteins (such as damaged, misfolded, or aggregated proteins) is associated with many diseases, including cancer. Therefore, maintaining proteostasis is critical for cellular health. Currently, genetic methods for modulating proteostasis, such as RNA interference and CRISPR knockout, lack spatial and temporal precision. They are also not suitable for depleting already-synthesized proteins. Similarly, molecular tools like PROTACs and molecular glue face challenges in drug design and discovery. To directly control targeted protein degradation within cells, we introduce an intrabody-based optogenetic toolbox named Flash-Away integrates the light-responsive ubiquitination activity of the RING domain of TRIM21 for protein degradation, coupled with specific intrabodies for precise targeting. Upon exposure to blue light, Flash-Away enables rapid and targeted degradation of selected proteins. This versatility is demonstrated through successful application to diverse protein targets, including actin, MLKL, and ALFA-tag fused proteins. This innovative light-inducible protein degradation system offers a powerful approach to investigate the functions of specific proteins within physiological contexts. Moreover, Flash-Away presents potential opportunities for clinical translational research and precise medical interventions, advancing the prospects of precision medicine.
The human body depends on accurate genetic instructions to keep its cells working properly. Cancer begins to form when these instructions become disrupted. As genetic mistakes build up over time, cells can lose their normal limits on growth and start multiplying in an uncontrolled way. Chromosomal abnormalities – numerical and structural defects in chromosomes – are often one of the earliest changes that push healthy cells toward becoming cancerous.
Researchers in the Korbel Group at EMBL Heidelberg have created a new AI-based tool that gives scientists a way to closely examine how these chromosomal abnormalities develop. The insights gained from this approach may eventually clarify some of the earliest steps that lead to cancer.
“Chromosomal abnormalities are a main driver for particularly aggressive cancers, and they’re highly linked to patient death, metastasis, recurrence, chemotherapy resistance, and fast tumor onset,” said Jan Korbel, senior scientist at EMBL and senior author of the new paper, published in the journal Nature. “We wanted to understand what determines the likelihood that cells undergo such chromosomal alterations, and what’s the rate at which such abnormalities arise when a still normal cell divides.”
The corpus callosum is critical for nearly everything the brain does, from coordinating the movement of our limbs in sync to integrating sights and sounds, to higher-order thinking and decision-making. Abnormalities in its shape and size have long been linked to disorders such as ADHD, bipolar disorder, and Parkinson’s disease. Until now, the genetic underpinnings of this vital structure remained largely unknown.
In the new study, published in Nature Communications, the team analyzed brain scans and genetic data from over 50,000 people, ranging from childhood to late adulthood, with the help of a new tool the team created that leverages artificial intelligence.
“We developed an AI tool that finds the corpus callosum in different types of brain MRI scans and automatically takes its measurements,” said co-first author of the study. Using this tool, the researchers identified dozens of genetic regions that influence the size and thickness of the corpus callosum and its subregions.
The study revealed that different sets of genes govern the area versus the thickness of the corpus callosum—two features that change across the lifespan and play distinct roles in brain function. Several of the implicated genes are active during prenatal brain development, particularly in processes like cell growth, programmed cell death, and the wiring of nerve fibers across hemispheres.
Notably, the study found genetic overlap between the corpus callosum and the cerebral cortex—the outer layer of the brain responsible for memory, attention, and language—as well as with conditions such as ADHD and bipolar disorder.
For the first time, a research team has mapped the genetic architecture of a crucial part of the human brain known as the corpus callosum—the thick band of nerve fibers that connects the brain’s left and right hemispheres. The findings open new pathways for discoveries about mental illness, neurological disorders and other diseases related to defects in this part of the brain.
Amid concerns about the simultaneous spread of multiple respiratory diseases, such as colds and influenza, with the change of seasons in current times, a clinical study has scientifically proven that kimchi, a traditional Korean fermented food, enhances the function of human immune cells and maintains the balance of the immune system.
The World Institute of Kimchi has reported the results of a single-cell genetic analysis that suggests that kimchi consumption has immunomodulatory effects, which include the suppression of excessive immune responses while simultaneously enhancing defense functions.
The results of the research are published in npj Science of Food.
A low dose of aspirin each day may significantly reduce the chances of colon and rectal cancer returning in certain cases, a new clinical trial has found.
Led by researchers from the Karolinska Institute and Karolinska University Hospital in Sweden, the study involved 626 people with stages 1 to 3 colon or rectal cancer, and specific genetic mutations in the cancer tumors.
Previous studies have suggested that cancers with these mutations – specifically in the PIK3 signaling pathway – could be targeted by aspirin, but this is the first time the hypothesis has been tested in a randomized clinical trial.
Genetic engineering and human enhancement are no longer science fiction — they’re here right now. In this episode of Longevity Science News, we explore the rise of gene therapy, anti-aging biotechnology, and the first wave of GMO Humans using real genetic enhancements to increase muscle, extend telomeres, boost IQ, and slow biological aging.
If you’re interested in longevity, life extension, biohacking, genetic modification, or cutting-edge anti-aging research, this video breaks down everything you need to know about the future of human evolution — and the people already jumping in.
HUME BODY ANALYZER: Use Code: LONGEVITY for up to 50% OFF https://humehealth.com//discount/LONG… FEATURED: BioViva Keynote by Liz Parrish Watch the full keynote here: • The First Person to Take Gene Therapy for… This talk covers viral vectors, telomere extension, muscle-growth gene therapies, cognitive enhancement, dementia treatment, and the global expansion of experimental genetic clinics. Chapters: 00:00 – Cold Open — FDA Gene Cures 00:35 – Liz Parrish & BioViva 01:35 – Sebastian A. Brunemeier 02:48 – HUME Body Pod 03:55 – Currently Available Genetic Cures 04:48 – How To Get Access 08:00 – Safety & Pricing 08:22 – Right to Try Debate 09:20 – Follistatin Results 10:50 – Telomere Extension 11:50 – Klotho & IQ Boost 13:26 – IQ & Society 14:35 – Dementia Gene Therapy 15:40 – Custom Therapies 16:20 – Conclusion • FDA-approved genetic cures • BioViva’s gene enhancement results • Follistatin gene therapy for muscle growth • Telomerase (TERT) for biological age reversal • Klotho gene therapy for cognitive enhancement • Dementia gene therapy case studies • Medical tourism for experimental gene treatments • How to access unapproved gene therapies • AI’s role in designing next-gen genetic interventions • Personalized & bespoke gene therapies • Ethical questions about enhancing IQ, strength, and lifespan • The future of human evolution & GMO humans 👤 EXPERTS & SOURCES FEATURED Liz Parrish — BioViva Sciences LinkedIn: / lizlparrish Sebastian Brunemeier — Cambrian Bio / Long Game Ventures LinkedIn: / sebastianlongbio Long Game Ventures: / longgame-vc Wired Magazine — Medical Tourism & Gene Therapy Pricing https://www.wired.com/story/bioviva-g… Extended Interview: Montana Senator Ken Bogner • Ken Bogner Full Interview 🔗 FULL INTERVIEWS & BONUS CONTENT Get extended conversations, deep dives, and behind-the-scenes research on Patreon: 👉 / u29506604 💬 JOIN THE DISCUSSION Would you use gene therapy to slow aging? Would you enhance your muscle, intelligence, or longevity? Do you think we should expand access to experimental anti-aging treatments? Let me know in the comments. 🧪 Longevity Science News PRODUCTION CREDITS ⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺ Executive Producer – Keith Comito @Retromancers Host, Producer, Writer – @emmettshort
🔬 FEATURED: BioViva Keynote by Liz Parrish. Watch the full keynote here: • The First Person to Take Gene Therapy for…
This talk covers viral vectors, telomere extension, muscle-growth gene therapies, cognitive enhancement, dementia treatment, and the global expansion of experimental genetic clinics.
DNA methylation has shown great potential in Alzheimer’s disease (AD) blood diagnosis. However, the ability of long non-coding RNAs (lncRNAs), which can be modified by DNA methylation, to serve as noninvasive biomarkers for AD diagnosis remains unclear.
We performed logistic regression analysis of DNA methylation data from the blood of patients with AD compared and normal controls to identify epigenetically regulated (ER) lncRNAs. Through five machine learning algorithms, we prioritized ER lncRNAs associated with AD diagnosis. An AD blood diagnosis model was constructed based on lncRNA methylation in Australian Imaging, Biomarkers, and Lifestyle (AIBL) subject and verified in two large blood-based studies, the European collaboration for the discovery of novel biomarkers for Alzheimer’s disease (AddNeuroMed) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). In addition, the potential biological functions and clinical associations of lncRNAs were explored, and their neuropathological roles in AD brain tissue were estimated via cross-tissue analysis.
We characterized the ER lncRNA landscape in AD blood, which is strongly related to AD occurrence and process. Fifteen ER lncRNAs were prioritized to construct an AD blood diagnostic and nomogram model. The receiver operating characteristic (ROC) curve and the decision and calibration curves show that the model has good prediction performance. We found that the targets and lncRNAs were correlated with AD clinical features. Moreover, cross-tissue analysis revealed that the lncRNA ENSG0000029584 plays both diagnostic and neuropathological roles in AD.
Every second, trillions of tiny parcels travel through your bloodstream—carrying vital information between your body’s cells. Now, scientists at the Baker Heart and Diabetes Institute have opened this molecular mail for the first time, revealing its contents in astonishing detail.
In research published in Nature Cell Biology, Professor David W. Greening and Dr. Alin Rai have mapped the complete molecular blueprint of extracellular vesicles (EVs)—nanosized particles in blood that act as the body’s secret messengers.
For decades, researchers have known that EVs exist, ferrying proteins, fats, and genetic material that mirror the health of their cells of origin. But because blood is a complex mixture—packed with cholesterol, antibodies, and millions of other particles—isolating EVs has long been one of science’s toughest challenges.
The human gut renews itself faster than any other tissue: every few days, new cells are created from specialized stem cells. However, as we get older, epigenetic changes build up in these stem cells. These are chemical markers on the DNA that act like switches, determining which genes remain active.
The study, recently published in Nature Aging, was conducted by an international team led by Prof. Francesco Neri from the University of Turin, Italy, and shows that changes in the gut do not occur randomly. Rather, a specific pattern develops over the course of aging, which the researchers refer to as ACCA (Aging-and Colon Cancer-Associated) drift. “We observe an epigenetic pattern that becomes increasingly apparent with age,” explains Prof. Neri, former group leader at the Leibniz Institute on Aging—Fritz Lipmann Institute in Jena.
Genes that maintain the balance in healthy tissue are particularly affected, including those that control the renewal of the intestinal epithelium via the Wnt signaling pathway. The changes described as “drifting” can be detected not only in the aging gut, but also in almost all colon cancer samples examined. This suggests that the aging of stem cells creates an environment that promotes the development of cancer.
